Table 3.

Mean exploration times (±SEM) in the sample and test phases of the object-in-place task after scopolamine or mecamylamine infusions

InfusateTiming of infusionConditionExploration in sample phase (s)Exploration in test phase (s)
NovelFamiliarTotal
ScopolamineBefore sample phaseVehicle92.7 ± 2.721.3 ± 2.19.1 ± 1.030.5 ± 2.1
Scopolamine92.5 ± 3.717.7 ± 1.520.3 ± 2.738.1 ± 3.6
Before test phaseVehicle86.8 ± 4.429.2 ± 3.111.1 ± 1.240.3 ± 3.2
Scopolamine78.6 ± 2.225.2 ± 2.011.2 ± 1.736.5 ± 3.1
MecamylamineBefore sample phaseVehicle80.5 ± 4.119.6 ± 2.57.4 ± 0.827.0 ± 2.4
Mecamylamine79.6 ± 5.614.9 ± 1.817.9 ± 1.532.8 ± 2.8
Before test phaseVehicle84.3 ± 2.322.6 ± 2.78.6 ± 0.531.3 ± 2.8
Mecamylamine79.8 ± 4.523.4 ± 2.010.7 ± 2.134.1 ± 3.7
  • Exploration in the test phase is presented as mean time spent exploring the novel and familiar objects separately and as total exploration.